Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2025-10-29	텔라세벡 기전, 세계가 움직인다…J&J도 합류
2025-10-23	큐리언트 텔라세벡, ID Week에서 호주 40명 임상결과 발표…”100% 완치 확정”
2025-09-25	큐리언트, 시나픽스와 차세대 이중 페이로드 ADC 개발 협력
2025-09-25	Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC.
2025-07-30	큐리언트, 아드릭세티닙 cGvHD 임상 유럽 확대…글로벌 개발 본격화

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More